- South Korea
- /
- Healthcare Services
- /
- KOSE:A008930
Hanmi Science Third Quarter 2024 Earnings: EPS: ₩263 (vs ₩453 in 3Q 2023)
Hanmi Science (KRX:008930) Third Quarter 2024 Results
Key Financial Results
- Revenue: ₩322.5b (up 4.2% from 3Q 2023).
- Net income: ₩17.8b (down 42% from 3Q 2023).
- Profit margin: 5.5% (down from 10.0% in 3Q 2023). The decrease in margin was driven by higher expenses.
- EPS: ₩263 (down from ₩453 in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Hanmi Science shares are down 2.1% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 1 warning sign for Hanmi Science that you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if Hanmi Science might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSE:A008930
Hanmi Science
Through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally.
Mediocre balance sheet and slightly overvalued.